Rep. Josh Gottheimer Unloads Shares of Insmed, Inc. (NASDAQ:INSM)

Posted by Brenda Bartman on Jul 9th, 2026

Representative Josh Gottheimer (Democratic-New Jersey) recently sold shares of Insmed, Inc. (NASDAQ:INSM). In a filing disclosed on July 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insmed stock on June 10th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Nintendo (OTCMKTS:NTDOY) on 6/17/2026.
Sold $1,001 – $15,000 in shares of Agree Realty (NYSE:ADC) on 6/1/2026.
Sold $1,001 – $15,000 in shares of Novozymes A/S (OTCMKTS:NVZMY) on 6/1/2026.
Sold $1,001 – $15,000 in shares of Nestle (OTCMKTS:NSRGY) on 6/1/2026.
Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 6/1/2026.
Sold $1,001 – $15,000 in shares of Booking (NASDAQ:BKNG) on 6/1/2026.
Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 5/27/2026.
Purchased $1,001 – $15,000 in shares of Lumentum (NASDAQ:LITE) on 5/22/2026.
Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 5/22/2026.
Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 5/21/2026.

Insmed Trading Up 3.3%

Shares of INSM stock opened at $116.53 on Thursday. The business has a 50-day moving average price of $107.94 and a two-hundred day moving average price of $138.83. Insmed, Inc. has a 12-month low of $90.39 and a 12-month high of $212.75. The company has a quick ratio of 4.10, a current ratio of 4.47 and a debt-to-equity ratio of 0.80. The firm has a market cap of $25.26 billion, a P/E ratio of -20.27 and a beta of 0.78.

Insmed (NASDAQ:INSM – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company’s revenue was up 229.7% on a year-over-year basis. During the same period in the prior year, the company earned ($1.42) EPS. Equities analysts anticipate that Insmed, Inc. will post -2.55 EPS for the current fiscal year.

Insider Buying and Selling at Insmed

In related news, CFO Sara Bonstein sold 2,404 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $245,857.08. Following the transaction, the chief financial officer owned 69,082 shares in the company, valued at $7,065,016.14. The trade was a 3.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Roger Adsett sold 2,370 shares of Insmed stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total transaction of $242,379.90. Following the completion of the transaction, the chief operating officer directly owned 98,603 shares of the company’s stock, valued at $10,084,128.81. This trade represents a 2.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 54,590 shares of company stock valued at $6,078,011 over the last ninety days. Company insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CoreCap Advisors LLC bought a new position in shares of Insmed in the 4th quarter worth about $27,000. Reflection Asset Management purchased a new stake in Insmed in the fourth quarter worth about $30,000. GraniteShares Advisors LLC purchased a new stake in Insmed in the fourth quarter worth about $30,000. CIBC Private Wealth Group LLC increased its stake in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares in the last quarter. Finally, Raiffeisen Bank International AG bought a new position in shares of Insmed during the fourth quarter valued at approximately $32,000.

Analysts Set New Price Targets

Several research firms have commented on INSM. Stifel Nicolaus lifted their price target on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Roth Capital reaffirmed a “buy” rating on shares of Insmed in a report on Monday, June 8th. Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Truist Financial cut their price target on shares of Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $211.86.

Check Out Our Latest Stock Report on Insmed

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.